JP2016065094A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016065094A5 JP2016065094A5 JP2015232562A JP2015232562A JP2016065094A5 JP 2016065094 A5 JP2016065094 A5 JP 2016065094A5 JP 2015232562 A JP2015232562 A JP 2015232562A JP 2015232562 A JP2015232562 A JP 2015232562A JP 2016065094 A5 JP2016065094 A5 JP 2016065094A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- pharmaceutical composition
- antibody
- composition according
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41053310P | 2010-11-05 | 2010-11-05 | |
| US61/410,533 | 2010-11-05 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013537154A Division JP2014503482A (ja) | 2010-11-05 | 2011-11-04 | Ｉｌ−１７アンタゴニストを用いて関節リウマチを治療する方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016139469A Division JP6250109B2 (ja) | 2010-11-05 | 2016-07-14 | Ｉｌ−１７アンタゴニストを用いて関節リウマチを治療する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016065094A JP2016065094A (ja) | 2016-04-28 |
| JP2016065094A5 true JP2016065094A5 (enExample) | 2016-09-01 |
| JP6049843B2 JP6049843B2 (ja) | 2016-12-21 |
Family
ID=44906168
Family Applications (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013537154A Pending JP2014503482A (ja) | 2010-11-05 | 2011-11-04 | Ｉｌ−１７アンタゴニストを用いて関節リウマチを治療する方法 |
| JP2015232562A Active JP6049843B2 (ja) | 2010-11-05 | 2015-11-30 | Ｉｌ−１７アンタゴニストを用いて関節リウマチを治療する方法 |
| JP2016139469A Active JP6250109B2 (ja) | 2010-11-05 | 2016-07-14 | Ｉｌ−１７アンタゴニストを用いて関節リウマチを治療する方法 |
| JP2017223669A Active JP6515168B2 (ja) | 2010-11-05 | 2017-11-21 | Ｉｌ−１７アンタゴニストを用いて関節リウマチを治療する方法 |
| JP2019076324A Pending JP2019142912A (ja) | 2010-11-05 | 2019-04-12 | Ｉｌ−１７アンタゴニストを用いて関節リウマチを治療する方法 |
| JP2021031383A Pending JP2021104995A (ja) | 2010-11-05 | 2021-03-01 | Ｉｌ−１７アンタゴニストを用いて関節リウマチを治療する方法 |
| JP2023084472A Pending JP2023109910A (ja) | 2010-11-05 | 2023-05-23 | Ｉｌ－１７アンタゴニストを用いて関節リウマチを治療する方法 |
| JP2025034128A Pending JP2025102772A (ja) | 2010-11-05 | 2025-03-04 | Ｉｌ－１７アンタゴニストを用いて関節リウマチを治療する方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013537154A Pending JP2014503482A (ja) | 2010-11-05 | 2011-11-04 | Ｉｌ−１７アンタゴニストを用いて関節リウマチを治療する方法 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016139469A Active JP6250109B2 (ja) | 2010-11-05 | 2016-07-14 | Ｉｌ−１７アンタゴニストを用いて関節リウマチを治療する方法 |
| JP2017223669A Active JP6515168B2 (ja) | 2010-11-05 | 2017-11-21 | Ｉｌ−１７アンタゴニストを用いて関節リウマチを治療する方法 |
| JP2019076324A Pending JP2019142912A (ja) | 2010-11-05 | 2019-04-12 | Ｉｌ−１７アンタゴニストを用いて関節リウマチを治療する方法 |
| JP2021031383A Pending JP2021104995A (ja) | 2010-11-05 | 2021-03-01 | Ｉｌ−１７アンタゴニストを用いて関節リウマチを治療する方法 |
| JP2023084472A Pending JP2023109910A (ja) | 2010-11-05 | 2023-05-23 | Ｉｌ－１７アンタゴニストを用いて関節リウマチを治療する方法 |
| JP2025034128A Pending JP2025102772A (ja) | 2010-11-05 | 2025-03-04 | Ｉｌ－１７アンタゴニストを用いて関節リウマチを治療する方法 |
Country Status (30)
| Country | Link |
|---|---|
| US (10) | US9744234B2 (enExample) |
| EP (6) | EP4116325A1 (enExample) |
| JP (8) | JP2014503482A (enExample) |
| KR (5) | KR20140008305A (enExample) |
| CN (2) | CN104800844A (enExample) |
| AU (1) | AU2011325134B2 (enExample) |
| BR (1) | BR112013011176A2 (enExample) |
| CA (2) | CA3116725C (enExample) |
| CL (1) | CL2013001213A1 (enExample) |
| CY (1) | CY1121802T1 (enExample) |
| DE (1) | DE20187001T1 (enExample) |
| DK (2) | DK3111954T3 (enExample) |
| ES (3) | ES3030036T3 (enExample) |
| FI (1) | FI3757126T3 (enExample) |
| HR (2) | HRP20251174T1 (enExample) |
| HU (1) | HUE044038T2 (enExample) |
| IL (4) | IL311014A (enExample) |
| LT (2) | LT3111954T (enExample) |
| MA (1) | MA34647B1 (enExample) |
| MX (1) | MX362591B (enExample) |
| PH (1) | PH12013500890A1 (enExample) |
| PL (1) | PL3111954T3 (enExample) |
| PT (2) | PT3757126T (enExample) |
| RS (1) | RS67377B1 (enExample) |
| RU (1) | RU2582937C2 (enExample) |
| SG (2) | SG189138A1 (enExample) |
| SI (1) | SI3111954T1 (enExample) |
| TR (1) | TR201909531T4 (enExample) |
| TW (3) | TWI604851B (enExample) |
| WO (1) | WO2012059598A2 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG185354A1 (en) | 2010-05-20 | 2012-12-28 | Ablynx Nv | Biological materials related to her3 |
| HRP20251174T1 (hr) | 2010-11-05 | 2025-11-21 | Novartis Ag | Postupci za liječenje psorijatičnog artritisa uporabom il-17 antagonista |
| UA117218C2 (uk) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
| SG10201707813YA (en) | 2011-10-11 | 2017-11-29 | Medimmune Llc | Cd40l-specific tn3-derived scaffolds and methods of use thereof |
| EP2809660B1 (en) | 2012-02-02 | 2016-01-20 | Ensemble Therapeutics Corporation | Macrocyclic compounds for modulating il-17 |
| US20140004131A1 (en) * | 2012-05-04 | 2014-01-02 | Novartis Ag | Antibody formulation |
| WO2014155278A2 (en) | 2013-03-26 | 2014-10-02 | Novartis Ag | Methods of treating autoimmune diseases using il-17 antagonists |
| AU2014338991B2 (en) | 2013-10-22 | 2020-06-11 | Novimmune S.A. | Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of TLR4 ligands and other biomarkers |
| KR20160113268A (ko) * | 2014-01-28 | 2016-09-28 | 베이징 한미 파마슈티컬 컴퍼니 리미티드 | 이기능 융합단백질,이의 제조방법 및 용도 |
| EP3603748A1 (en) | 2014-05-13 | 2020-02-05 | MedImmune Limited | Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer |
| US11548940B2 (en) | 2014-05-15 | 2023-01-10 | Rani Therapeutics, Llc | Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| EP3142645A4 (en) | 2014-05-15 | 2017-12-27 | Rani Therapeutics, LLC | Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins |
| FR3021976B1 (fr) * | 2014-06-06 | 2018-11-02 | Hospices Civils De Lyon | Marqueur biologique permettant d'evaluer le niveau pro-inflammatoire dependant de la contribution fonctionnelle de l'il-17 chez un individu |
| US20160002326A1 (en) * | 2014-06-10 | 2016-01-07 | Abbvie Inc. | Compositions and methods for treating rheumatoid arthritis |
| NL2013007B1 (en) * | 2014-06-16 | 2016-07-05 | Ablynx Nv | Methods of treating TTP with immunoglobulin single variable domains and uses thereof. |
| CA2960754A1 (en) | 2014-09-10 | 2016-03-17 | Novartis Ag | Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients |
| CN107106655A (zh) * | 2014-10-22 | 2017-08-29 | 阿尔莫生物科技股份有限公司 | 使用白细胞介素‑10治疗疾病和病症的方法 |
| AR103173A1 (es) * | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| AR103172A1 (es) * | 2014-12-22 | 2017-04-19 | Novartis Ag | Reducción selectiva de residuos de cisteina en anticuerpos il-17 |
| CA2978449A1 (en) | 2015-03-02 | 2016-09-09 | 180 Therapeutics Lp | Method of treating a localized fibrotic disorder using an il-33 antagonist |
| EP3167892A1 (en) | 2015-11-10 | 2017-05-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for preventing or treating imflammatory bowel diseases |
| EP3365011A1 (en) * | 2015-10-19 | 2018-08-29 | Novartis AG | Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (il-17) antagonists |
| EP3504648A1 (en) * | 2016-08-23 | 2019-07-03 | CSL Behring GmbH | Method of preventing acute attacks of hereditary angioedema associated with c1 esterase inhibitor deficiency |
| CN111344043A (zh) * | 2017-11-02 | 2020-06-26 | 诺华股份有限公司 | 使用白细胞介素-17(il-17)拮抗剂治疗肌腱病的方法 |
| GB201719447D0 (en) * | 2017-11-23 | 2018-01-10 | Ucb Biopharma Sprl | Pharmaceutical composition |
| CN119746057A (zh) * | 2018-05-09 | 2025-04-04 | 诺华股份有限公司 | 卡那吉努单抗的用途 |
| AU2019346457B2 (en) * | 2018-09-26 | 2025-05-08 | Viela Bio, Inc. | CD40l antagonist and uses thereof |
| AU2020213265B2 (en) * | 2019-01-22 | 2025-01-16 | F. Hoffmann-La Roche Ag | Methods of treating rheumatoid arthritis, chronic spontaneous urticaria, and systemic lupus erythematosis using an inhibitor of Bruton's tyrosine kinase |
| MX2021009851A (es) | 2019-02-18 | 2021-09-10 | Lilly Co Eli | Formulacion de anticuerpos terapeuticos. |
| KR102169901B1 (ko) * | 2019-05-17 | 2020-10-26 | 연세대학교 산학협력단 | Dna 메틸화를 이용한 면역 항암 요법의 치료 반응에 관한 정보 제공 방법 및 이를 이용한 키트 |
| CN110179746A (zh) * | 2019-05-17 | 2019-08-30 | 通化东宝生物科技有限公司 | 一种稳定的苏金单抗注射剂及其制备方法 |
| MX2022001607A (es) * | 2019-08-05 | 2022-03-11 | Evelo Biosciences Inc | Composiciones y metodos para tratar la psoriasis y la dermatitis atopica usando prevotella histicola. |
| EP4031570A1 (en) * | 2019-09-20 | 2022-07-27 | Novartis AG | Methods of treating autoimmune diseases using interleukin-17 (il-17) antagonists |
| AU2020386669A1 (en) | 2019-11-19 | 2022-06-02 | Novartis Ag | Methods of treating Lupus Nephritis using interleukin-17 (IL-17) antagonists |
| CN112915201B (zh) * | 2019-12-06 | 2023-06-27 | 珠海市丽珠单抗生物技术有限公司 | 包含抗il-17抗体的液体制剂 |
| WO2021146850A1 (en) * | 2020-01-20 | 2021-07-29 | Tsinghua University | A critical role of febrile temperature in regulating interleukin (il) -17 producing cells via smad4 |
| WO2022113105A1 (en) * | 2020-11-25 | 2022-06-02 | Dr. Reddy's Laboratories Limited | Stable therapeutic protein formulation and methods of making the same |
| TW202241505A (zh) * | 2021-01-04 | 2022-11-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抗il-17抗體治療自體免疫性疾病和炎症的方法 |
| TW202246329A (zh) * | 2021-03-03 | 2022-12-01 | 大陸商蘇州盛迪亞生物醫藥有限公司 | 抗il-17抗體治療自體免疫性疾病和炎症的方法 |
| KR102339377B1 (ko) * | 2021-03-29 | 2021-12-13 | 김지혜 | 사용자 맞춤형 문화 예술 컨텐츠 제공 방법 및 장치 |
| CN117500834A (zh) * | 2021-06-21 | 2024-02-02 | 百时美施贵宝公司 | 使用蔗糖、甘露糖醇和甘氨酸来减少高浓度冻干生物制剂药物产品的重构时间 |
| CN114306594A (zh) * | 2021-12-21 | 2022-04-12 | 华中科技大学同济医学院附属协和医院 | 地舒单抗在制备治疗膝关节骨性关节炎的药物中的应用 |
| EP4406553A1 (en) | 2023-01-27 | 2024-07-31 | Fresenius Kabi Deutschland GmbH | Stable secukinumab biopharmaceutical composition |
| WO2024156841A1 (en) | 2023-01-27 | 2024-08-02 | Fresenius Kabi Deutschland Gmbh | Biopharmaceutical composition |
| WO2025071335A1 (ko) * | 2023-09-27 | 2025-04-03 | 삼성바이오에피스 주식회사 | 항-il-17 항체의 안정한 액상 제형 |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0565233A (ja) | 1991-03-08 | 1993-03-19 | Mitsui Toatsu Chem Inc | モノクローナル抗体含有凍結乾燥製剤 |
| US5250442A (en) * | 1993-04-08 | 1993-10-05 | Orestes Cabezas | Method of treating rheumatoid arthritis using tetracycline |
| US6309636B1 (en) * | 1995-09-14 | 2001-10-30 | Cancer Research Institute Of Contra Costa | Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides |
| EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| US20050147609A1 (en) | 1998-05-15 | 2005-07-07 | Genentech, Inc. | Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis |
| JP2000186046A (ja) | 1998-10-14 | 2000-07-04 | Snow Brand Milk Prod Co Ltd | 慢性関節リウマチ治療剤及び診断方法 |
| US6395511B1 (en) | 1998-11-27 | 2002-05-28 | Darwin Discovery, Ltd. | Nucleic acids encoding a novel family of TGF-β binding proteins from humans |
| US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
| JP4159682B2 (ja) | 1998-12-22 | 2008-10-01 | 株式会社クラレ | 止血材 |
| ATE454137T1 (de) | 2001-07-25 | 2010-01-15 | Facet Biotech Corp | Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab |
| CA2466641A1 (en) | 2001-11-09 | 2003-05-22 | Centocor, Inc. | Lyophilized monoclonal antibody compositions |
| AU2003223214B2 (en) | 2002-03-01 | 2008-09-18 | Celltech R & D, Inc. | Methods to increase or decrease bone density |
| AU2003276430A1 (en) | 2002-06-14 | 2003-12-31 | Stowers Institute For Medical Research | Wise/sost nucleic acid sequences and amino acid sequences |
| US6974701B2 (en) | 2003-03-21 | 2005-12-13 | Hemovations, Llc | Erythrocyte sedimentation rate (ESR) test measurement instrument of unitary design and method of using the same |
| NZ544618A (en) | 2003-06-16 | 2009-02-28 | Celltech R & D Inc | Antibodies specific for sclerostin and methods for increasing bone mineralization |
| US8461155B2 (en) | 2003-09-22 | 2013-06-11 | University Of Connecticut | Sclerostin and the inhibition of WNT signaling and bone formation |
| US8039642B2 (en) | 2003-12-09 | 2011-10-18 | Life Technologies Corporation | Pyrenyloxysulfonic acid fluorescent agents |
| GB0417487D0 (en) * | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| JP3936365B2 (ja) | 2004-09-14 | 2007-06-27 | ソニーケミカル＆インフォメーションデバイス株式会社 | 機能素子実装モジュール及びその製造方法 |
| DK1865986T3 (en) | 2005-03-08 | 2016-04-11 | Pfizer Prod Inc | The anti-CTLA-4 antibody compositions |
| US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| EP1957474A4 (en) | 2005-11-04 | 2011-08-24 | Harvard College | SYNTHESIS OF FTSZ HEMMERN |
| MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
| WO2007074880A1 (ja) | 2005-12-28 | 2007-07-05 | Chugai Seiyaku Kabushiki Kaisha | 抗体含有安定化製剤 |
| JP5068270B2 (ja) * | 2006-01-31 | 2012-11-07 | ノバルティス アーゲー | 癌を処置するためのｉｌ−１７アンタゴニスト抗体 |
| TW200815469A (en) | 2006-06-23 | 2008-04-01 | Astrazeneca Ab | Compounds |
| WO2008030611A2 (en) | 2006-09-05 | 2008-03-13 | Medarex, Inc. | Antibodies to bone morphogenic proteins and receptors therefor and methods for their use |
| WO2008029908A1 (fr) | 2006-09-07 | 2008-03-13 | Kyowa Hakko Kirin Co., Ltd. | Préparation pharmaceutique lyophilisée stable comprenant un anticorps |
| US7833527B2 (en) | 2006-10-02 | 2010-11-16 | Amgen Inc. | Methods of treating psoriasis using IL-17 Receptor A antibodies |
| UA99716C2 (ru) * | 2006-10-02 | 2012-09-25 | Кирин-Амген Инк. | Антитело, которое специфично связывает человеческий il-17 рецептор а (il-17ra) |
| EP2460828A3 (en) | 2006-11-10 | 2012-08-08 | UCB Pharma, S.A. | Antibodies and diagnostics |
| US20100036091A1 (en) | 2006-11-10 | 2010-02-11 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
| MX2009008096A (es) | 2007-02-02 | 2009-08-07 | Novartis Ag | Moduladores de los componentes de enlace de esclerostatina para el tratamiento de trastornos relacionados con los huesos. |
| MY149129A (en) | 2007-03-20 | 2013-07-15 | Lilly Co Eli | Anti-sclerostin antibodies |
| UA96473C2 (ru) | 2007-03-22 | 2011-11-10 | Имклоун Ллк | Жидкая стойкая композиция, которая содержит антитело imc-а12 |
| AU2008232903B9 (en) * | 2007-03-30 | 2013-09-05 | Medimmune Llc | Antibodies with decreased deamidation profiles |
| EP2171449A2 (en) * | 2007-06-20 | 2010-04-07 | Schering Corporation | Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease |
| US7720605B2 (en) | 2007-06-22 | 2010-05-18 | Weyerhaeuser Nr Company | Identifying vegetation attributes from LiDAR data |
| CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
| TWI489993B (zh) | 2007-10-12 | 2015-07-01 | Novartis Ag | 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法 |
| BRPI0819688A2 (pt) | 2007-12-14 | 2015-06-16 | Amgen Inc | Processo para tratamento de fratura óssea com anticorpos anti-esclerostina. |
| SG191639A1 (en) | 2008-06-03 | 2013-07-31 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| US20090301682A1 (en) | 2008-06-05 | 2009-12-10 | Baker Hughes Incorporated | Casting furnace method and apparatus |
| AU2009268585C1 (en) | 2008-07-08 | 2014-10-02 | Abbvie Inc. | Prostaglandin E2 dual variable domain immunoglobulins and uses thereof |
| WO2010034443A1 (en) | 2008-09-29 | 2010-04-01 | F. Hoffmann-La Roche Ag | Antibodies against human il 17 and uses thereof |
| EP2358392B1 (en) | 2008-11-12 | 2019-01-09 | MedImmune, LLC | Antibody formulation |
| FR2938547B1 (fr) | 2008-11-14 | 2012-11-16 | Total Raffinage Marketing | Liant synthetique clair |
| US20110256130A1 (en) | 2008-12-01 | 2011-10-20 | Joshua Robert Schultz | Methods of treating inflammatory disorders |
| PE20160653A1 (es) | 2009-03-05 | 2016-07-24 | Abbvie Inc | Proteinas de union a il-17 |
| EP2625199B1 (en) | 2010-10-08 | 2017-11-22 | Novartis AG | Methods of treating psoriasis using il-17 antagonists |
| HRP20251174T1 (hr) | 2010-11-05 | 2025-11-21 | Novartis Ag | Postupci za liječenje psorijatičnog artritisa uporabom il-17 antagonista |
| WO2012082573A1 (en) | 2010-12-13 | 2012-06-21 | Novartis Ag | Predictive methods and methods of treating arthritis using il-17 antagonists |
| EP2783014A1 (en) | 2011-11-21 | 2014-10-01 | Novartis AG | Methods of treating psoriatic arthritis (psa) using il-17 antagonists and psa response or non- response alleles |
| KR20150010709A (ko) | 2012-04-20 | 2015-01-28 | 노파르티스 아게 | Il-17 길항제를 사용하는 강직성 척추염의 치료 방법 |
| WO2014155278A2 (en) | 2013-03-26 | 2014-10-02 | Novartis Ag | Methods of treating autoimmune diseases using il-17 antagonists |
| EP3365011A1 (en) | 2015-10-19 | 2018-08-29 | Novartis AG | Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (il-17) antagonists |
| US11280479B2 (en) | 2017-10-18 | 2022-03-22 | The Sloan Company | Sign box light module |
-
2011
- 2011-11-04 HR HRP20251174TT patent/HRP20251174T1/hr unknown
- 2011-11-04 PT PT201870011T patent/PT3757126T/pt unknown
- 2011-11-04 EP EP22180976.7A patent/EP4116325A1/en active Pending
- 2011-11-04 SG SG2013023064A patent/SG189138A1/en unknown
- 2011-11-04 KR KR1020137011539A patent/KR20140008305A/ko not_active Ceased
- 2011-11-04 DE DE20187001.1T patent/DE20187001T1/de active Pending
- 2011-11-04 SG SG10201505624VA patent/SG10201505624VA/en unknown
- 2011-11-04 KR KR1020187004058A patent/KR20180019247A/ko not_active Ceased
- 2011-11-04 TW TW100140410A patent/TWI604851B/zh active
- 2011-11-04 DK DK16163440.7T patent/DK3111954T3/da active
- 2011-11-04 EP EP11778903.2A patent/EP2635303A2/en not_active Withdrawn
- 2011-11-04 WO PCT/EP2011/069476 patent/WO2012059598A2/en not_active Ceased
- 2011-11-04 CN CN201510199026.8A patent/CN104800844A/zh active Pending
- 2011-11-04 TW TW105142587A patent/TWI618543B/zh active
- 2011-11-04 EP EP19162707.4A patent/EP3542820A1/en not_active Withdrawn
- 2011-11-04 RU RU2013125775/15A patent/RU2582937C2/ru active
- 2011-11-04 TW TW104103341A patent/TWI616204B/zh active
- 2011-11-04 PL PL16163440T patent/PL3111954T3/pl unknown
- 2011-11-04 EP EP20187001.1A patent/EP3757126B1/en active Active
- 2011-11-04 SI SI201131750T patent/SI3111954T1/sl unknown
- 2011-11-04 KR KR1020187034385A patent/KR20180129991A/ko not_active Ceased
- 2011-11-04 ES ES21180656T patent/ES3030036T3/es active Active
- 2011-11-04 KR KR1020157003096A patent/KR20150020734A/ko not_active Ceased
- 2011-11-04 TR TR2019/09531T patent/TR201909531T4/tr unknown
- 2011-11-04 DK DK20187001.1T patent/DK3757126T3/da active
- 2011-11-04 CA CA3116725A patent/CA3116725C/en active Active
- 2011-11-04 KR KR1020167014431A patent/KR20160067984A/ko not_active Ceased
- 2011-11-04 IL IL311014A patent/IL311014A/en unknown
- 2011-11-04 EP EP21180656.7A patent/EP3912640B1/en active Active
- 2011-11-04 US US13/877,585 patent/US9744234B2/en active Active
- 2011-11-04 EP EP16163440.7A patent/EP3111954B1/en not_active Revoked
- 2011-11-04 RS RS20251090A patent/RS67377B1/sr unknown
- 2011-11-04 ES ES20187001T patent/ES2804624T1/es active Pending
- 2011-11-04 PT PT16163440T patent/PT3111954T/pt unknown
- 2011-11-04 PH PH1/2013/500890A patent/PH12013500890A1/en unknown
- 2011-11-04 BR BR112013011176-3A patent/BR112013011176A2/pt not_active IP Right Cessation
- 2011-11-04 LT LTEP16163440.7T patent/LT3111954T/lt unknown
- 2011-11-04 CN CN2011800529537A patent/CN103189074A/zh active Pending
- 2011-11-04 LT LTEP20187001.1T patent/LT3757126T/lt unknown
- 2011-11-04 MX MX2013005060A patent/MX362591B/es active IP Right Grant
- 2011-11-04 CA CA2813849A patent/CA2813849C/en active Active
- 2011-11-04 ES ES16163440T patent/ES2733712T3/es active Active
- 2011-11-04 HU HUE16163440A patent/HUE044038T2/hu unknown
- 2011-11-04 FI FIEP20187001.1T patent/FI3757126T3/fi active
- 2011-11-04 JP JP2013537154A patent/JP2014503482A/ja active Pending
- 2011-11-04 AU AU2011325134A patent/AU2011325134B2/en not_active Expired - Fee Related
-
2013
- 2013-03-18 IL IL225309A patent/IL225309B/en active IP Right Grant
- 2013-05-03 CL CL2013001213A patent/CL2013001213A1/es unknown
- 2013-05-03 MA MA35873A patent/MA34647B1/fr unknown
-
2015
- 2015-11-30 JP JP2015232562A patent/JP6049843B2/ja active Active
-
2016
- 2016-07-14 JP JP2016139469A patent/JP6250109B2/ja active Active
-
2017
- 2017-07-20 US US15/654,854 patent/US10363307B2/en active Active
- 2017-11-21 JP JP2017223669A patent/JP6515168B2/ja active Active
-
2018
- 2018-10-24 IL IL262559A patent/IL262559B/en unknown
-
2019
- 2019-04-12 JP JP2019076324A patent/JP2019142912A/ja active Pending
- 2019-06-12 US US16/439,423 patent/US20190307880A1/en not_active Abandoned
- 2019-06-26 HR HRP20191162TT patent/HRP20191162T1/hr unknown
- 2019-07-03 CY CY20191100708T patent/CY1121802T1/el unknown
-
2020
- 2020-03-19 US US16/824,613 patent/US11534491B2/en active Active
- 2020-12-18 US US17/127,758 patent/US20210128726A1/en not_active Abandoned
-
2021
- 2021-02-02 US US17/165,729 patent/US20210177966A1/en not_active Abandoned
- 2021-03-01 JP JP2021031383A patent/JP2021104995A/ja active Pending
- 2021-04-25 IL IL282625A patent/IL282625A/en unknown
- 2021-12-08 US US17/545,894 patent/US12465635B2/en active Active
-
2022
- 2022-10-21 US US18/048,797 patent/US20230293683A1/en active Pending
- 2022-12-02 US US18/061,221 patent/US20230346926A1/en active Pending
-
2023
- 2023-05-23 JP JP2023084472A patent/JP2023109910A/ja active Pending
-
2025
- 2025-02-24 US US19/061,831 patent/US20250205332A1/en active Pending
- 2025-03-04 JP JP2025034128A patent/JP2025102772A/ja active Pending